沙库巴曲缬沙坦治疗腹膜透析患者慢性左心衰竭的效果

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨沙库巴曲缬沙坦治疗腹膜透析患者慢性左心衰竭的临床效果。方法选取2017年4月至2021年4月于深圳市龙岗中心医院腹膜透析中心随访的60 例伴慢性左心衰竭腹膜透析患者为研究对象进行回顾性分析，按照不同治疗方案将其分为观察组（30 例）和对照组（30 例）。观察组使用沙库巴曲缬沙坦治疗，对照组使用缬沙坦治疗，两组患者均治疗6 个月。比较两组患者的总有效率、血压、左室射血分数（LVEF）和N 末端B 型利钠肽原（NT-proBNP）水平。结果治疗6 个月后，观察组的总有效率高于对照组，差异有统计学意义（P＜0.05）。两组患者治疗后的收缩压与舒张压比较，差异无统计学意义（P＞0.05）。观察组治疗后的LVEF 高于对照组，差异有统计学意义（P＜0.05）。观察组治疗后的NT-proBNP 水平低于对照组，差异有统计学意义（P＜0.05）。结论沙库巴曲缬沙坦能有效治疗腹膜透析患者慢性左心衰竭。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郑佳麒
	沈明静

关键词 ：沙库巴曲缬沙坦, 慢性左心衰竭, 肾衰竭, 腹膜透析, 疗效

Abstract：Objective To investigate the clinical effect of Sacubitril Valsartan in the treatment of chronic left heart failure in patients with peritoneal dialysis. Methods A total of 60 peritoneal dialysis patients with chronic left heart failure who were followed up in Peritoneal Dialysis Center of Central Hospital of Longgang District in Shenzhen City from April 2017 to April 2021 were selected as the subjects for retrospective analysis. According to different treatment plan,they were divided into the observation group (n=30) and the control group (n=30). The observation group was treated with Sacubitril Valsartan, and the control group was treated with Valsartan. Both groups were treated for 6 months. The total effective rates, blood pressure, left ventricular ejection fractions (LVEF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were compared between the two groups. Results After 6 months of treatment, the total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05). There were no significant differences in systolic blood pressure and diastolic blood pressure between the two groups after treatment (P＞0.05). The LVEF of the observation group after treatment was higher than that of the control group, and the difference was statistically significant (P＜0.05). The level of NT-proBNP in the observation group after treatment was lower than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion Sacubitril Valsartan can effectively treat chronic left heart failure in patients with peritoneal dialysis.

Key words： Sacubitril Valsartan Chronic left heart failure Renal failure Peritoneal dialysis Therapeutic effect

引用本文:

郑佳麒；沈明静. 沙库巴曲缬沙坦治疗腹膜透析患者慢性左心衰竭的效果[J]. 中国当代医药, 2022, 29(16): 148-151.
ZHENG Jiaqi ；SHEN Mingjing. Effect of Sacubitril Valsartan in the treatment of chronic left heart failure in patients with peritoneal dialysis. 中国当代医药, 2022, 29(16): 148-151.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I16/148